TY - JOUR
T1 - Association between mutant IDHs and tumorigenesis in gliomas
AU - Ohba, Shigeo
AU - Hirose, Yuichi
N1 - Publisher Copyright:
© 2018, The Japanese Society for Clinical Molecular Morphology.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.
AB - To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.
UR - http://www.scopus.com/inward/record.url?scp=85045078709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045078709&partnerID=8YFLogxK
U2 - 10.1007/s00795-018-0189-8
DO - 10.1007/s00795-018-0189-8
M3 - Review article
C2 - 29633022
AN - SCOPUS:85045078709
SN - 1860-1480
VL - 51
SP - 194
EP - 198
JO - Medical Molecular Morphology
JF - Medical Molecular Morphology
IS - 4
ER -